Marc Sundook

Role: Area Sales Manager at Castle Biosciences, Inc.
Location: Pompano Beach, FL, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Marc Sundook

Experience in launching and promoting pharmaceuticals, Pharmacogenomics & AI within a…

Experience

Area Sales Manager
Castle Biosciences, Inc.
Oct 2022 — Present
PGx-Pharmacogenomics Precision Medicine Behavioral Health & Pain IDgenetix

Education

Florida Atlantic University
BA, College of Communications & Journalism

Skills

Gastroenterology
Neurology
Training
Sales Effectiveness
B2b
Account Management
Sales Management
Strategic Planning
Recruiting
Team Building
Pharmaceutical Sales
Cross-Functional Team Leadership
Hospital Sales
Sales Operations
Negotiation
Leadership
Marketing
Cns Disorders
Hospitals
Business Development
Healthcare
Pharmaceutical Industry
Product Launch
Neuroscience
Crm
Sales
Cardiology
Managed Care

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@castlebiosciences.com
Personal email
•••••@•••••.com
Direct dial
+17•••••••93

Unlock verified contacts

Free to start · No credit card required

Current company

Castle Biosciences, Inc.

Biotechnology Research · 781 employees · Founded 2008 · Friendswood, Texas, United States

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

castlebiosciences.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Marc Sundook

Experience

Area Sales Manager

Education

Florida Atlantic University

Skills

Find verified contacts for anyone on LinkedIn